Abstract
BackgroundThis meta-analysis aimed to investigate the efficacy and radiation-related toxicities of upper-neck irradiation (UNI) over whole-neck irradiation (WNI) in patients with unilateral or bilateral node-negative nasopharyngeal carcinoma. MethodsWe conducted a systematic review to identify studies comparing survival and toxicities between UNI and WNI by searching key databases up to Aug 2022. Hazard ratios (HRs) with 95% confidence intervals (CIs) for regional recurrence-free survival (RRFS), local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) were pooled using R 4.0.5. Risk ratios (RRs) for acute and late radiation-related toxicities were also pooled. Subgroup analyses according to nodal status, radiotherapy techniques, and study type were conducted. ResultsEight studies enrolling 2568 patients were included. Patients who received UNI showed similar RRFS (HR 0.99, 95% CI 0.57–1.74, P = 0.975), LRFS (HR 0.86, 95% CI 0.53–1.41, P = 0.559), DMFS (HR 0.90, 95% CI 0.63–1.29, P = 0.581), PFS (1.10, 95% CI 0.73–1.67, P = 0.642), and OS (1.03, 95% CI 0.77–1.37, P = 0.866) compared with WNI. When stratified by nodal status, the pooled HRs for RRFS in patient subgroups with stage N0 disease, stage N1 with only retropharyngeal lymph nodes metastasis, and unilateral cervical lymph node metastasis were 0.46 (95% CI 0.04–5.16, P = 0.529), 1.12 (95% CI 0.29–4.38, P = 0.872), and 1.02 (95% CI 0.48–2.16, P = 0.968) respectively, none of which reached statistical significance. UNI was associated with lower incidences of grade 1–2 hypothyroidism (RR 0.75, 95% CI 0.57–0.97, P = 0.031) and grade 1–2 dysphagia (RR 0.58, 95% CI 0.42–0.80, P < 0.001) compared with WNI. ConclusionUNI had similar efficacy and fewer toxicities compared with WNI for patients with unilateral or bilateral node-negative nasopharyngeal carcinoma. The lower-neck sparing of the uninvolved neck is a valid option for N0, N1, and even unilateral N3 diseases in nasopharyngeal carcinoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.